Karuna Therapeutics Inc Quick Ratio (KRTX) starting from the fourth quarter 2023 to fourth quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Karuna Therapeutics Inc   (NASDAQ: KRTX)

Karuna Therapeutics Inc 's Quick Ratio

KRTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2023, Quick Ratio deteriorated to 26.1 below Karuna Therapeutics Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Quick Ratio than Karuna Therapeutics Inc in fourth quarter 2023. While Quick Ratio total ranking in the fourth quarter 2023 has deteriorated compared to the prior quarter from 84 to 126.

Explain Quick Ratio?
How much Cash & cash equivalents KRTX´s has?
What are KRTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KRTX Quick Ratio (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4
Y / Y Current Liabilities Change 42.56 % 20.18 % 61.74 % 58.49 % 67.94 %
Y / Y Cash & cash equivalent Change 12.35 % 12.54 % 252.59 % 232.69 % 127.54 %
Quick Ratio MRQ 26.1 27.4 37.21 58.42 33.11
KRTX's Total Ranking # 126 # 84 # 67 # 13 # 83
Seq. Current Liabilities Change -1.18 % 26.85 % 52.96 % -25.66 % -16.69 %
Seq. Cash & cash equivalent Change -5.87 % -6.61 % -2.57 % 31.17 % -5.7 %



Quick Ratio fourth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 25
Healthcare Sector # 35
Overall Market # 126


Quick Ratio Statistics
High Average Low
90.34 42.65 4.73
(Jun 30 2020)   (Jun 30 2019)




Financial Statements
Karuna Therapeutics Inc 's Current Liabilities $ 48 Millions Visit KRTX's Balance sheet
Karuna Therapeutics Inc 's Cash & cash equivalent $ 1,263 Millions Visit KRTX's Balance sheet
Source of KRTX's Sales Visit KRTX's Sales by Geography


Cumulative Karuna Therapeutics Inc 's Quick Ratio

KRTX's Quick Ratio for the trailling 12 Months

KRTX Quick Ratio

 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth 40.81 % 45.66 % 82.8 % 98.95 % 116.29 %
Y / Y Cash & cash equivalent TTM Growth 74.17 % 111.96 % 183.54 % 112.05 % 50.24 %
Quick Ratio TTM 34.21 36.64 37.73 33.91 27.66
Total Ranking TTM # 2886 # 2326 # 2304 # 2501 # 2695
Seq. Current Liabilities TTM Growth 9.84 % 5.94 % 11.9 % 8.14 % 13.63 %
Seq. Cash & cash equivalent TTM Growth 2.58 % 2.86 % 24.51 % 32.57 % 24.84 %

Quick ratio ranking by company, industry and sector >> Back to KRTX Financial Strength Comparisons >> Go to Compare KRTX Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q4 2023 to $48.39 millions, cumulative Quick Ratio decreased to 34.21 below the Karuna Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 510 other companies have achieved higher Quick Ratio than Karuna Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2023 from 2326 to 2886.

Explain Quick Ratio?
How much Cash & cash equivalents KRTX´s has?
What are KRTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 511
Healthcare Sector # 973
Within the Market # 2886


trailing twelve months Quick Ratio Statistics
High Average Low
75.15 45.2 24.33
(Sep 30 2020)   (Jun 30 2022)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Altimmune inc   71.13 $ 197.815  Millions$ 2.781  Millions
Verona Pharma Plc  69.21 $ 271.772  Millions$ 3.927  Millions
Arca Biopharma Inc  58.76 $ 37.431  Millions$ 0.637  Millions
Moonlake Immunotherapeutics  51.28 $ 511.008  Millions$ 9.966  Millions
Third Harmonic Bio Inc   49.66 $ 269.070  Millions$ 5.418  Millions
Nuvation Bio Inc   43.74 $ 611.213  Millions$ 13.974  Millions
Merrimack Pharmaceuticals Inc  42.80 $ 18.875  Millions$ 0.441  Millions
Ars Pharmaceuticals Inc   42.79 $ 228.360  Millions$ 5.337  Millions
Genmab A  40.36 $ 2,204.000  Millions$ 54.609  Millions
Climb Bio Inc   37.70 $ 106.798  Millions$ 2.833  Millions
Rafael Holdings Inc  36.93 $ 79.212  Millions$ 2.145  Millions
Tao Synergies Inc   34.18 $ 30.100  Millions$ 0.881  Millions
Design Therapeutics Inc   29.29 $ 281.798  Millions$ 9.622  Millions
Bicara Therapeutics Inc   28.62 $ 230.440  Millions$ 8.053  Millions
Morphic Holding inc   28.43 $ 704.349  Millions$ 24.776  Millions
Roivant Sciences Ltd   27.24 $ 6,670.810  Millions$ 244.899  Millions
Lixte Biotechnology Holdings Inc   26.81 $ 4.203  Millions$ 0.157  Millions
Upstream Bio Inc   26.41 $ 109.810  Millions$ 4.158  Millions
Karuna Therapeutics Inc   26.10 $ 1,262.813  Millions$ 48.392  Millions
Crinetics Pharmaceuticals Inc   26.04 $ 1,144.421  Millions$ 43.942  Millions
Akero Therapeutics Inc   24.42 $ 550.010  Millions$ 22.522  Millions
Belite Bio Inc  24.27 $ 88.157  Millions$ 3.633  Millions
Xenon Pharmaceuticals Inc   23.40 $ 638.082  Millions$ 27.273  Millions
Immunome Inc   23.37 $ 142.151  Millions$ 6.082  Millions
Anixa Biosciences Inc   23.06 $ 46.773  Millions$ 2.028  Millions
Nuvalent Inc   22.62 $ 719.905  Millions$ 31.823  Millions
Janux Therapeutics Inc   22.31 $ 344.028  Millions$ 15.422  Millions
Xbiotech Inc   22.25 $ 200.023  Millions$ 8.990  Millions
Astria Therapeutics Inc   21.97 $ 246.530  Millions$ 11.221  Millions
Pliant Therapeutics Inc   21.81 $ 495.544  Millions$ 22.724  Millions

Date modified: 2026-09-08T15:11:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.